Company on the Biopôle campus that funds and supports start-ups located on the campus through the Biopôle Investment Programme.
Profile being verified
What they look for
The Biopôle Investment Programme (BIP), which succeeds the Start-up Fund launched in 2021, is a 24-month programme offering non-dilutive funding of up to CHF 90 000, due diligence training and introductions to investors. The CHF 250 000 Pre-Clinical Top-Up is reserved for participants that have raised at least CHF 250 000 in external capital; Switchkine was the first beneficiary. Participants are selected by an Investment Advisory Board.
Recent investments
Recorded Swiss rounds: Ai.Qimia (grant, amount not disclosed, November 2025, lead), Calico Biosystems (grant, amount not disclosed, November 2025, lead), Emovo Care (grant, amount not disclosed, November 2025, lead), Evidone (grant, amount not disclosed, November 2025, lead), Precise Health (grant, amount not disclosed, November 2025, lead), Prevision Medicine (grant, amount not disclosed, November 2025, lead), Switchkine (grant, CHF 250 000, November 2025, lead).
Rounds tracked by FundSwiss
- Dexterous EndoscopesGrant · Amount not disclosed
- Ai.QimiaGrant · Amount not disclosed
- Calico BiosystemsGrant · Amount not disclosed
- Emovo CareGrant · Amount not disclosed
- EvidoneGrant · Amount not disclosed
- Precise HealthGrant · Amount not disclosed
- Prevision MedicineGrant · Amount not disclosed
- SwitchkineGrant · CHF 250,000